Celestial Therapeutics Joins Johnson & Johnson Innovation - JLABS
Celestial Therapeutics Inc. (“Celestial”), a biotechnology company developing novel next-generation vaccines and therapeutics leveraging its proprietary platform technologies to treat, prevent and cure infectious diseases, inflammatory conditions and cancers is pleased to announce that it has been accepted into Johnson & Johnson Innovation – JLABS (“JLABS”) as a resident company at its flagship site in San Diego, California.
JLABS is one of the largest global networks of health incubators pioneering the next wave of healthcare solutions with early-stage innovators. Powered by Johnson & Johnson, JLABS empowers its member companies working across the spectrum of healthcare with the resources, mentorship, partnerships and venture connections to accelerate their science.
Dr. Ajay Gupta, Co-founder, President, Chairman & CEO of Celestial, said:
“We are excited and honored to join JLABS as a resident company as it will enable Celestial to leverage JLABS state of the art facilities, vast network, expertise and resources within several specialties and gain access to world-class mentorship, industry connections, partnership opportunities and research capabilities within the Johnson & Johnson Innovation ecosystem to help accelerate the progress of our R&D efforts and the growth of our pipeline. Becoming a JLABS member is a significant achievement for Celestial and a testament to Celestial’s technology, team, and represents a major milestone in the growth of the company for advancing its lead candidates into the clinic”.
Celestial Therapeutics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers. More information: http://jlabs.jnjinnovation.com/
About Celestial Therapeutics
Celestial is a California based startup biotechnology company developing a first in class of a new class of non-steroidal anti-inflammatories, a new class of dual-modal antiviral and anti-inflammatory drugs and novel mRNA vaccines & therapeutics for conditions which currently lack safe and effective treatments. Celestial’s mission is to effectively treat respiratory infections & inflammatory conditions, cancers, prevent pandemics, save lives, reduce healthcare costs and address unmet medical needs for millions of patients worldwide. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies. Celestial’s lead therapeutic candidate, CT-02, is being developed as a first-ever broad spectrum dual-modal antiviral & anti-inflammatory inhalation therapeutic for treating lung infections due to Respiratory Syncytial Virus (RSV). Celestial’s new mRNA vaccine, CT-03 is being developed for the prevention of viral infections arising from Chikungunya leveraging its novel and proprietary next generation Stellar-mRNA platform. Celestial’s anti-inflammatory therapeutics have the potential to provide safer and more effective alternative treatments to the existing steroidal and non-steroidal anti-inflammatories currently on the market. The Celestial team consists of industry veterans and prominent academicians with a proven track record.
To learn more, visit https://www.celestialtherapeutics.com
Contacts:
Leontis Teryazos – CFO